Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 14, Issue 8, Pages -Publisher
SPRINGER
DOI: 10.1007/s11910-014-0472-6
Keywords
Amyloid; Pittsburgh compound B; Parkinson disease dementia; Dementia with Lewy bodies; PET
Categories
Funding
- National Parkinson Foundation
- National Institute of Neurological Disorders and Stroke NINDS
- National Institute of Mental Health
Ask authors/readers for more resources
Cognitive impairment and dementia are significant sequelae of Parkinson disease (PD) and comprise a key feature of dementia with Lewy bodies (DLB), a disease with similar clinical and neuropathological features. Multiple independent causes have been implicated in PD dementia (PDD) and DLB, among them the accumulation of beta-amyloid, a neuropathological hallmark of Alzheimer disease. Over the last decade, PET imaging has emerged as a viable method to measure amyloid burden in the human brain and relate it to neurodegenerative diseases. This article reviews what amyloid imaging has taught us about PDD and DLB. Current data suggest that brain amyloid deposition tends to be more marked in DLB, yet contributes to cognitive impairment in both DLB and PD. These results are broadly consistent with neuropathology and CSF studies. beta-Amyloid may interact synergistically with other pathological processes in PD and DLB to contribute to cognitive impairment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available